Health regulator authorizes Fiocruz to produce key Covid-19 vaccine component in Brazil

Health regulator ANVISA considers, however,that Fiocruz will still need to make commercial-scale batches of the vaccine with locally produced API.

RIO DE JANEIRO, BRAZIL -  The National Health Regulator (ANVISA), in a decision taken this Friday, April 30, authorized the Oswaldo Cruz Foundation (Fiocruz) to produce in Brazil the active pharmaceutical ingredient (API) of the Oxford/AstraZeneca Covid-19 vaccine.

ANVISA's decision was based on a technical inspection at Fiocruz's Bio-Manguinhos plant. The API is the essential biological raw material for the production of immunizers. Today, Brazil only produces vaccines by importing APIs, mainly from China.

However, the agency considers that Fiocruz still needs to make commercial-scale batches of the vaccine with locally produced API. When the . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?